Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 24,500 shares of Clearside Biomedical stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $7.52, for a total value of $184,240.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.49, for a total value of $63,665.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.98, for a total value of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.02, for a total value of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.57, for a total value of $185,465.00.

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up 0.80% during trading on Friday, reaching $7.60. The company had a trading volume of 224,557 shares. Clearside Biomedical, Inc. has a 12 month low of $6.50 and a 12 month high of $25.08. The firm’s 50 day moving average price is $7.68 and its 200 day moving average price is $7.97. The firm’s market capitalization is $192.55 million.

Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Wednesday, August 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.13). The company had revenue of $0.13 million for the quarter. Clearside Biomedical had a negative net margin of 27,225.52% and a negative return on equity of 65.78%. Equities analysts predict that Clearside Biomedical, Inc. will post ($2.10) EPS for the current year.

WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/16/clearside-biomedical-inc-clsd-director-clay-thorp-sells-24500-shares.html.

Large investors have recently made changes to their positions in the business. Nationwide Fund Advisors grew its holdings in Clearside Biomedical by 118.3% during the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock valued at $107,000 after buying an additional 6,343 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Clearside Biomedical during the 2nd quarter valued at $117,000. Parametric Portfolio Associates LLC acquired a new stake in Clearside Biomedical during the 2nd quarter valued at $122,000. ProShare Advisors LLC grew its holdings in Clearside Biomedical by 4.0% during the 2nd quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock valued at $135,000 after buying an additional 563 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Clearside Biomedical during the 2nd quarter valued at $137,000. Hedge funds and other institutional investors own 52.45% of the company’s stock.

A number of equities analysts recently commented on the company. ValuEngine upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Zacks Investment Research downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a research report on Monday, August 7th. JMP Securities assumed coverage on Clearside Biomedical in a research report on Thursday, May 25th. They set an “outperform” rating and a $21.00 price objective on the stock. Finally, TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Clearside Biomedical has a consensus rating of “Buy” and a consensus target price of $19.00.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Stock Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related stocks with our FREE daily email newsletter.